Oxaliplatin
- Generic Name
- Oxaliplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O4Pt
- CAS Number
- 61825-94-3
- Unique Ingredient Identifier
- 04ZR38536J
- Background
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemic...
- Indication
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
- Associated Conditions
- Advanced Colorectal Cancer, Stage III Colon Cancer
- Associated Therapies
- -
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 89
- Registration Number
- NCT06489808
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 134
- Registration Number
- NCT06462053
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT06455124
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 53
- Registration Number
- NCT06451211
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06447636
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06446388
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 84
- Registration Number
- NCT06441565
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Pei-Rong Ding
- Target Recruit Count
- 66
- Registration Number
- NCT06417476
- Locations
- 🇨🇳
651 Dongfeng Road East, Guangzhou, Guangdong, China
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
- Conditions
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT06396585
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 46
- Registration Number
- NCT06390982
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.